A number of other research analysts have also recently commented on GBT. JPMorgan Chase & Co. reissued a buy rating on shares of Global Blood Therapeutics in a report on Thursday, September 5th. Wedbush reissued a buy rating and issued a $120.00 price target on shares of Global Blood Therapeutics in a report on Wednesday, October 9th. ValuEngine raised Global Blood Therapeutics from a hold rating to a buy rating in a report on Friday, November 1st. William Blair reissued a buy rating on shares of Global Blood Therapeutics in a report on Tuesday, October 8th. Finally, Cantor Fitzgerald reissued an overweight rating on shares of Global Blood Therapeutics in a report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $88.08.
Shares of NASDAQ:GBT traded down $0.17 on Friday, hitting $47.00. 752,700 shares of the company traded hands, compared to its average volume of 765,230. The stock has a 50 day simple moving average of $49.25 and a 200-day simple moving average of $53.30. The company has a quick ratio of 16.79, a current ratio of 16.79 and a debt-to-equity ratio of 0.03. Global Blood Therapeutics has a 52 week low of $30.15 and a 52 week high of $64.94. The company has a market cap of $2.99 billion, a PE ratio of -13.78 and a beta of 1.57.
Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.03) by ($0.04). During the same period in the prior year, the firm earned ($0.83) earnings per share. As a group, sell-side analysts anticipate that Global Blood Therapeutics will post -3.99 earnings per share for the current year.
In other news, insider De Dominicis Robert 490,012 shares of the firm’s stock in a transaction that occurred on Tuesday, October 22nd. Also, insider Tricia Borga Suvari sold 3,327 shares of Global Blood Therapeutics stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $48.45, for a total value of $161,193.15. Following the completion of the sale, the insider now directly owns 12,386 shares in the company, valued at approximately $600,101.70. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,698 shares of company stock worth $711,058. Corporate insiders own 4.30% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in GBT. Taylor Wealth Management Partners increased its stake in Global Blood Therapeutics by 0.5% in the 2nd quarter. Taylor Wealth Management Partners now owns 44,801 shares of the company’s stock worth $2,357,000 after acquiring an additional 217 shares during the last quarter. Fox Run Management L.L.C. bought a new position in shares of Global Blood Therapeutics during the 2nd quarter valued at approximately $290,000. Segantii Capital Management Ltd bought a new position in shares of Global Blood Therapeutics during the 2nd quarter valued at approximately $2,630,000. FNY Investment Advisers LLC bought a new position in shares of Global Blood Therapeutics during the 2nd quarter valued at approximately $1,014,000. Finally, Strs Ohio increased its position in shares of Global Blood Therapeutics by 59.0% during the 2nd quarter. Strs Ohio now owns 6,200 shares of the company’s stock valued at $326,000 after purchasing an additional 2,300 shares during the last quarter. 97.85% of the stock is currently owned by institutional investors and hedge funds.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Featured Story: How to Invest in Growth Stocks
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.